Dysthymic Disorder

Chronically depressed mood that occurs for most of the day more days than not for at least 2 years. The required minimum duration in children to make this diagnosis is 1 year. During periods of depressed mood, at least 2 of the following additional symptoms are present: poor appetite or overeating, insomnia or hypersomnia, low energy or fatigue, low self esteem, poor concentration or difficulty making decisions, and feelings of hopelessness. (DSM-IV)
Also Known As:
Disorder, Dysthymic; Dysthymic Disorders
Networked: 148 relevant articles (21 outcomes, 54 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Major Depressive Disorder (Major Depressive Disorders)
2. Depressive Disorder (Melancholia)
3. Dysthymic Disorder
4. Personality Disorders (Personality Disorder)
5. Borderline Personality Disorder (Personality Disorders, Borderline)


1. Bogetto, Filippo: 4 articles (01/2005 - 01/2002)
2. Hellerstein, David J: 3 articles (07/2012 - 05/2004)
3. Tedeschini, Enrico: 3 articles (10/2011 - 04/2011)
4. Papakostas, George I: 3 articles (10/2011 - 04/2011)
5. Klein, Daniel N: 3 articles (07/2005 - 12/2002)
6. Roose, Steven P: 3 articles (01/2005 - 03/2002)
7. Devanand, D P: 3 articles (01/2005 - 03/2002)
8. Dunner, David L: 3 articles (10/2003 - 01/2002)
9. Hotopf, Matthew: 2 articles (01/2015 - 01/2003)
10. Stewart, Jonathan W: 2 articles (07/2012 - 09/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Dysthymic Disorder:
1. Antidepressive Agents (Antidepressants)IBA
2. Fluoxetine (Prozac)FDA LinkGeneric
3. Imipramine (Janimine)FDA LinkGeneric
4. Citalopram (Escitalopram)FDA Link
5. tianeptine (Stablon)IBA
6. RitanserinIBA
7. venlafaxine (Effexor)FDA LinkGeneric
8. Bupropion (Wellbutrin)FDA LinkGeneric
06/01/2001 - "Bupropion sustained-release for the treatment of dysthymic disorder: an open-label study."
06/01/2001 - "Many studies of antidepressants in the treatment of dysthymic disorder (DD) have been conducted, but none has included bupropion sustained-release (SR). "
09/01/2009 - "Relatively treatment-naive depressed outpatients (with DSM-IV diagnoses of major depressive disorder, dysthymic disorder, or depression not otherwise specified) were initially treated with a combination of escitalopram (ESC) plus bupropion (BUP), using rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15 in an open-label, 8-week study. "
01/01/2013 - "We describe the case of a 67-year-old man known for dysthymic disorder in remission on quetiapine and venlafaxine who experienced a first lifetime episode of hypomania with the introduction of bupropion SR for smoking cessation. "
04/01/2011 - "We defined antidepressants as those with a letter of approval by the US, Canadian, or European Union drug regulatory agencies for treatment of MDD or dysthymic disorder, which included the following: amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, trimipramine, protriptyline, dothiepin, doxepin, lofepramine, amoxapine, maprotiline, amineptine, nomifensine, bupropion, phenelzine, tranylcypromine, isocarboxazid, moclobemide, brofaromine, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, zimelidine, tianeptine, ritanserin, trazodone, nefazodone, agomelatine, venlafaxine, desvenlafaxine, duloxetine, milnacipran, reboxetine, mirtazapine, and mianserin. "
9. Phenelzine (Nardil)FDA Link
10. Serotonin (5 Hydroxytryptamine)IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Continuous Positive Airway Pressure
3. Kampo Medicine (Kampo)
4. Transplantation (Transplant Recipients)
5. Hysterectomy